1114P - Trans-Arterial Chemo-Embolization (TACE) with CPT-11 charged microbeads in metastatic uveal melanoma patients: a retrospective analysis of 140 pati...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Skin Cancers
Biological Therapy
Presenter Sara Valpione
Citation Annals of Oncology (2014) 25 (suppl_4): iv374-iv393. 10.1093/annonc/mdu344
Authors S. Valpione1, M. Bazzi2, C. Aliberti3, R. Parrozzani4, J. Pigozzo1, P.L. Pilati5, E. Midena6, L.G. Campana7, V. Chiarion Sileni1
  • 1Melanoma And Esophageal Cancer Unit, Veneto Region Research institute, 35128 - Padova/IT
  • 2Statistics, University of Padova, Padova/IT
  • 3Radiologia Interventistica, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 4Ophthalmology, University of Padova, Padova/IT
  • 5Gastroenterological And Surgical Sciences, University of Padova, 35128 - Padova/IT
  • 6Department Of Ophthalmology, University of Padova, 35128 - Padova/IT
  • 7Melanoma And Sarcoma Unit, Veneto Region Oncology Research Institute (IOV-IRCCS), 35128 - Padova/IT



We retrospectively evaluated the benefit of transarterial chemoembolization with CPT-11-charged microbeads (TACE) in 140 uveal melanoma (mUM) patients with liver metastases.


This is s retrospective analysis of a prospectively maintained database ranging from September 1990 to April 2014. A model to avoid the confounding effect of liver substitution by metastases in the different cohorts of treatments was design using the Cox regression method under the verified hypothesis of proportional hazards.


Among 140 patients with liver metastases, 56 were treated with TACE as first line-therapy, 36 were dead at the time of the analysis; 84 patients received other first-line treatments (deaths = 84). The treatment with f-TACE conferred a not significant survival advantage (16.5 vs 12.2 months, respectively); when the two cohorts were analyzed comparing the two groups according to the percentage of liver involvement, there was significant evidence that TACE conferred a survival advantage for patients with worse hepatic metastatization (liver metastases = 20-50%: HR = 0.50, p = .048 and liver metastases => 50%: HR = 0.17, P = .009). The two treatment groups were homogeneous for prognostic factors. The treatment with TACE was not affected by severe toxicities.


TACE seems a tolerable regimen that confers an improvement in survival of uveal melanoma patients with liver metastases. Our data prompt for the conducting of prospective comparative studies confirming the efficacy of TACE and, in the future, we advise combination treatments with targeted drugs.


All authors have declared no conflicts of interest.